Hydrocodone

Last updated

Hydrocodone
Hydrocodone skeletal.svg
Hydrocodone-Spartan-PM3-3D-balls.png
Clinical data
Trade names Hysingla ER, Zohydro ER
Other namesDihydrocodeinone, hydrocodone bitartrate
AHFS/Drugs.com Monograph
MedlinePlus a601006
License data
Dependence
liability 		High [1]
Addiction
liability 		High
Routes of
administration 		Clinical: By mouth [2]
Others: Intranasal, rectal
Drug class Opioid
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Oral: 70% [4]
Protein binding Low [4] [5]
Metabolism Liver: CYP3A4 (major), CYP2D6 (minor) [6]
Metabolites • Norhydrocodone [6]
• Hydromorphone [6]
• Others [6]
Onset of action 10–20 minutes [2]
Elimination half-life Average: 3.8 hours [7]
Range: 3.3–4.4 hours [2]
Duration of action 4–8 hours [2]
Excretion Urine [8] [9]
Identifiers
  • 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.004.304 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C18H21NO3
Molar mass 299.370 g·mol−1
3D model (JSmol)
  • O=C4[C@@H]5Oc1c2c(ccc1OC)C[C@H]3N(CC[C@]25[C@H]3CC4)C
  • InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1 Yes check.svgY
  • Key:LLPOLZWFYMWNKH-CMKMFDCUSA-N Yes check.svgY
   (verify)

Hydrocodone, also known as dihydrocodeinone, is a semi-synthetic opioid used to treat pain and as a cough suppressant. [10] It is taken by mouth. [10] Typically, it is dispensed as the combination acetaminophen/hydrocodone or ibuprofen/hydrocodone for pain severe enough to require an opioid [11] [12] [13] and in combination with homatropine methylbromide to relieve cough. [10] It is also available by itself in a long-acting form sold under the brand name Zohydro ER, among others, to treat severe pain of a prolonged duration. [10] [14] Hydrocodone is a controlled drug: in the United States, it is classified as a Schedule II Controlled Substance.

Contents

Common side effects include dizziness, sleepiness, nausea, and constipation. [10] Serious side effects may include low blood pressure, seizures, QT prolongation, respiratory depression, and serotonin syndrome. [10] Rapidly decreasing the dose may result in opioid withdrawal. [10] Use during pregnancy or breastfeeding is generally not recommended. [15] Hydrocodone is believed to work by activating opioid receptors, mainly in the brain and spinal cord. [10] Hydrocodone 10 mg is equivalent to about 10 mg of morphine by mouth. [16]

Medical uses

Hydrocodone is used to treat moderate to severe pain. In liquid formulations, it is used to treat cough. [10] In one study comparing the potency of hydrocodone to that of oxycodone, it was found that it took 50% more hydrocodone to achieve the same degree of miosis (pupillary contraction). [17] The investigators interpreted this to mean that oxycodone is about 50% more potent than hydrocodone.

However, in a study of emergency department patients with fractures, it was found that an equal amount of either drug provided about the same degree of pain relief, indicating that there is little practical difference between them when used for that purpose. [18] Some references state that the analgesic action of hydrocodone begins in 20–30 minutes and lasts about 4–8 hours. [19] The manufacturer's information says onset of action is about 10–30 minutes and duration is about 4–6 hours. [20] Recommended dosing interval is 4–6 hours. Hydrocodone reaches peak serum levels after 1.3 hours. [21]

Available forms

Hydrocodone is available in a variety of formulations for oral administration: [22] [23] [24]

Hydrocodone is not available in parenteral or any other non-oral forms. [5] [2]

Side effects

Common side effects of hydrocodone are nausea, vomiting, constipation, drowsiness, dizziness, lightheadedness, anxiety, abnormally happy or sad mood, dry throat, difficulty urinating, rash, itching, and contraction of the pupils. Serious side effects include slowed or irregular breathing and chest tightness. [26]

Several cases of progressive bilateral hearing loss unresponsive to steroid therapy have been described as an infrequent adverse reaction to hydrocodone/paracetamol misuse. This adverse effect has been considered by some to be due to the ototoxicity of hydrocodone. [27] [28] Other researchers have suggested that paracetamol is the primary agent responsible for the ototoxicity. [29] [30]

The U.S. Food and Drug Administration (FDA) assigns the drug to pregnancy category C, meaning that no adequate and well-controlled studies in humans have been conducted. A newborn of a mother taking opioid medications regularly prior to the birth will be physically dependent. [31] [32] The baby may also exhibit respiratory depression if the opioid dose was high. [33] An epidemiological study indicated that opioid treatment during early pregnancy results in increased risk of various birth defects. [34]

Symptoms of hydrocodone overdose include narrowed or widened pupils; slow, shallow, or stopped breathing; slowed or stopped heartbeat; cold, clammy, or blue skin; excessive sleepiness; loss of consciousness; seizures; or death. [26]

Hydrocodone can be habit forming, causing physical and psychological dependence. Its abuse liability is similar to morphine and less than oxycodone. [35]

Interactions

Hydrocodone is metabolized by the cytochrome P450 enzymes CYP2D6 and CYP3A4, and inhibitors and inducers of these enzymes can modify hydrocodone exposure. [36] One study found that combination of paroxetine, a selective serotonin reuptake inhibitor (SSRI) and strong CYP2D6 inhibitor, with once-daily extended-release hydrocodone, did not modify exposure to hydrocodone or the incidence of adverse effects. [36] [37] These findings suggest that hydrocodone can be coadministered with CYP2D6 inhibitors without dosage modification. [36] [37] Conversely, combination of hydrocodone/acetaminophen with the antiviral regimen of ombitasvir, paritaprevir, ritonavir, and dasabuvir for treatment of hepatitis C increased peak concentrations of hydrocodone by 27%, total exposure by 90%, and elimination half-life from 5.1 hours to 8.0 hours. [38] Ritonavir is a strong CYP3A4 inhibitor as well as inducer of CYP3A and other enzymes, and the other antivirals are known to inhibit drug transporters like organic anion transporting polypeptide (OATP) 1B1 and 1B3, P-glycoprotein, and breast cancer resistance protein (BCRP). [38] The changes in hydrocodone levels are consistent with CYP3A4 inhibition by ritonavir. [38] Based on these findings, a 50% lower dose of hydrocodone and closer clinical monitoring was recommended when hydrocodone is used in combination with this antiviral regimen. [38]

People consuming alcohol, other opioids, anticholinergic antihistamines, antipsychotics, anxiolytics, or other central nervous system (CNS) depressants together with hydrocodone may exhibit an additive CNS depression. [33] Hydrocodone taken concomitantly with serotonergic medications like SSRI antidepressants may increase the risk of serotonin syndrome. [39]

Pharmacology

Pharmacodynamics

Hydrocodone (and metabolite) at opioid receptors
Compound Affinities (Ki Tooltip Inhibitor constant)RatioRef
MOR Tooltip μ-Opioid receptor DOR Tooltip δ-Opioid receptor KOR Tooltip κ-Opioid receptorMOR:DOR:KOR
Hydrocodone11.1 nM962 nM501 nM1:87:45 [40]
Hydromorphone 0.47 nM18.5 nM24.9 nM1:39:53 [41]

Equivalent analgesia doses [42] [43] [44]
Compound Route Dose
Codeine PO200 mg
HydrocodonePO30 mg
Hydromorphone PO7.5 mg
Hydromorphone IV1.5 mg
Morphine PO30 mg
Morphine IV10 mg
Oxycodone PO20 mg
Oxycodone IV10 mg
Oxymorphone PO10 mg
Oxymorphone IV1 mg

Hydrocodone is a highly selective full agonist of the μ-opioid receptor (MOR). [19] [45] [40] This is the main biological target of the endogenous opioid neuropeptide β-endorphin. [46] Hydrocodone has low affinity for the δ-opioid receptor (DOR) and the κ-opioid receptor (KOR), where it is an agonist similarly. [40]

Studies have shown hydrocodone is stronger than codeine but only one-tenth as potent as morphine at binding to receptors and reported to be only 59% as potent as morphine in analgesic properties. However, in tests conducted on rhesus monkeys, the analgesic potency of hydrocodone was actually higher than morphine. [7] Oral hydrocodone has a mean equivalent daily dosage (MEDD) factor of 0.4, meaning that 1 mg of hydrocodone is equivalent to 0.4 mg of intravenous morphine. However, because of morphine's low oral bioavailability, there is a 1:1 correspondence between orally administered morphine and orally administered hydrocodone. [47]

Pharmacokinetics

Absorption

Hydrocodone is only pharmaceutically available as an oral medication. [2] It is well-absorbed, but the oral bioavailability of hydrocodone is only approximately 25%. [4] [5] The onset of action of hydrocodone via this route is 10 to 20 minutes, with a peak effect (Tmax) occurring at 30 to 60 minutes, [42] and it has a duration of 4 to 8 hours. [2] The FDA label for immediate-release hydrocodone with acetaminophen does not include any information on the influence of food on its absorption or other pharmacokinetics. [48] Conversely, coadministration with a high-fat meal increases peak concentrations of different formulations of extended-release hydrocodone by 14 to 54%, whereas area-under-the-curve levels are not notably affected. [49] [50] [51] [52]

Distribution

The volume of distribution of hydrocodone is 3.3 to 4.7 L/kg. [5] The plasma protein binding of hydrocodone is 20 to 50%. [19]

Metabolism

In the liver, hydrocodone is transformed into several metabolites, including norhydrocodone, hydromorphone, 6α-hydrocodol (dihydrocodeine), and 6β-hydrocodol. [6] 6α- and 6β-hydromorphol are also formed, and the metabolites of hydrocodone are conjugated (via glucuronidation). [53] [54] Hydrocodone has a terminal half-life that averages 3.8 hours (range 3.3–4.4 hours). [7] [2] The hepatic cytochrome P450 enzyme CYP2D6 converts hydrocodone into hydromorphone, a more potent opioid (5-fold higher binding affinity to the MOR). [6] [55] However, extensive and poor cytochrome 450 CYP2D6 metabolizers had similar physiological and subjective responses to hydrocodone, and CYP2D6 inhibitor quinidine did not change the responses of extensive metabolizers, suggesting that inhibition of CYP2D6 metabolism of hydrocodone has no practical importance. [56] [57] Ultra-rapid CYP2D6 metabolizers (1–2% of the population) may have an increased response to hydrocodone; however, hydrocodone metabolism in this population has not been studied. [58]

Norhydrocodone, the major metabolite of hydrocodone, is predominantly formed by CYP3A4-catalyzed oxidation. [6] In contrast to hydromorphone, it is described as inactive. [55] However, norhydrocodone is actually a MOR agonist with similar potency to hydrocodone, but has been found to produce only minimal analgesia when administered peripherally to animals (likely due to poor blood–brain barrier and thus central nervous system penetration). [59] Inhibition of CYP3A4 in a child who was, in addition, a poor CYP2D6 metabolizer, resulted in a fatal overdose of hydrocodone. [60] Approximately 40% of hydrocodone metabolism is attributed to non-cytochrome P450-catalyzed reactions. [61]

Elimination

Hydrocodone is excreted in urine, mainly in the form of conjugates. [8] [9]

Chemistry

Detection in body fluids

Hydrocodone concentrations are measured in blood, plasma, and urine to seek evidence of misuse, to confirm diagnoses of poisoning, and to assist in investigations into deaths. Many commercial opiate screening tests react indiscriminately with hydrocodone, other opiates, and their metabolites, but chromatographic techniques can easily distinguish hydrocodone uniquely. Blood and plasma hydrocodone concentrations typically fall into the 5–30 μg/L range among people taking the drug therapeutically, 100–200 μg/L among recreational users, and 100–1,600 μg/L in cases of acute, fatal overdosage. Co-administration of the drug with food or alcohol can very significantly increase the resulting plasma hydrocodone concentrations that are subsequently achieved. [62] [63]

Synthesis

Hydrocodone is most commonly synthesized from thebaine, a constituent of opium latex from the dried poppy plant. Once thebaine is obtained, the reaction undergoes hydrogenation using a palladium catalyst. [64]

Structure

There are three important structures in hydrocodone: the amine group, which binds to the tertiary nitrogen binding site in the central nervous system's opioid receptor, the hydroxy group that binds to the anionic binding site, and the phenyl group which binds to the phenolic binding site. [65] This triggers a G protein activation and subsequent release of dopamine. [66]

History

Hydrocodone was first synthesized in Germany in 1920 by Carl Mannich and Helene Löwenheim. [67] It was approved by the Food and Drug Administration on 23 March 1943 for sale in the United States and approved by Health Canada for sale in Canada under the brand name Hycodan. [68] [69]

Hydrocodone was first marketed by Knoll as Dicodid, starting in February 1924 in Germany. This name is analogous to other products the company introduced or otherwise marketed: Dilaudid (hydromorphone, 1926), Dinarkon (oxycodone, 1917), Dihydrin (dihydrocodeine, 1911), and Dimorphan (dihydromorphine). Paramorfan is the trade name of dihydromorphine from another manufacturer, as is Paracodin, for dihydrocodeine. [70] [71]

Hydrocodone was patented in 1923, while the long-acting formulation was approved for medical use in the United States in 2013. [10] [72] It is most commonly prescribed in the United States, which consumed 99% of the worldwide supply as of 2010. [73] In 2018, it was the 402nd most commonly prescribed medication in the United States, with more than 400,000 prescriptions. [74]

Society and culture

Formulations

Several common imprints for hydrocodone are M365, M366, M367. [75]

Combination products

Hydrocodone and paracetamol (acetaminophen) 10-325 tablets (Mallinckrodt) Hydrocodone-paracetamol-5-500.jpg
Hydrocodone and paracetamol (acetaminophen) 10-325 tablets (Mallinckrodt)

Most hydrocodone formulations include a second analgesic, such as paracetamol (acetaminophen) or ibuprofen. Examples of hydrocodone combinations include Norco, Vicodin, Vicoprofen and Riboxen. [76]

The US government imposed tougher prescribing rules for hydrocodone in 2014, changing the drug from Schedule III to Schedule II. [77] [78] [79] [80] In 2011, hydrocodone products were involved in around 100,000 abuse-related emergency department visits in the United States, more than double the number in 2004. [81]

Related Research Articles

<span class="mw-page-title-main">Analgesic</span> Drugs used to achieve relief from pain

An analgesic drug, also called simply an analgesic, antalgic, pain reliever, or painkiller, is any member of the group of drugs used for pain management. Analgesics are conceptually distinct from anesthetics, which temporarily reduce, and in some instances eliminate, sensation, although analgesia and anesthesia are neurophysiologically overlapping and thus various drugs have both analgesic and anesthetic effects.

<span class="mw-page-title-main">Morphine</span> Pain medication of the opiate family

Morphine, formerly also called morphia, is an opiate that is found naturally in opium, a dark brown resin produced by drying the latex of opium poppies. It is mainly used as an analgesic. There are numerous methods used to administer morphine: oral; sublingual; via inhalation; injection into a muscle, injection under the skin, or injection into the spinal cord area; transdermal; or via rectal suppository. It acts directly on the central nervous system (CNS) to induce analgesia and alter perception and emotional response to pain. Physical and psychological dependence and tolerance may develop with repeated administration. It can be taken for both acute pain and chronic pain and is frequently used for pain from myocardial infarction, kidney stones, and during labor. Its maximum effect is reached after about 20 minutes when administered intravenously and 60 minutes when administered by mouth, while the duration of its effect is 3–7 hours. Long-acting formulations of morphine are sold under the brand names MS Contin and Kadian, among others. Generic long-acting formulations are also available.

<span class="mw-page-title-main">Oxycodone</span> Opioid medication

Oxycodone, sold under the brand name Roxicodone and OxyContin among others, is a semi-synthetic opioid used medically for treatment of moderate to severe pain. It is highly addictive and is a commonly abused drug. It is usually taken by mouth, and is available in immediate-release and controlled-release formulations. Onset of pain relief typically begins within fifteen minutes and lasts for up to six hours with the immediate-release formulation. In the United Kingdom, it is available by injection. Combination products are also available with paracetamol (acetaminophen), ibuprofen, naloxone, naltrexone, and aspirin.

<span class="mw-page-title-main">Paracetamol</span> Common medication for pain and fever

Paracetamol (acetaminophen) is a non-opioid analgesic and antipyretic agent used to treat fever and mild to moderate pain. It is a widely used over-the-counter medication. Common brand names include Tylenol and Panadol.

<span class="mw-page-title-main">Tramadol</span> Opioid pain medication

Tramadol, sold under the brand name Ultram among others, is an opioid pain medication and a serotonin–norepinephrine reuptake inhibitor (SNRI) used to treat moderately severe pain. When taken by mouth in an immediate-release formulation, the onset of pain relief usually begins within an hour. It is also available by injection. It is available in combination with paracetamol (acetaminophen).

<span class="mw-page-title-main">Opioid</span> Psychoactive chemical

Opioids are a class of drugs that derive from, or mimic, natural substances found in the opium poppy plant. Opioids work in the brain to produce a variety of effects, including pain relief. As a class of substances, they act on opioid receptors to produce morphine-like effects.

Oxycodone/paracetamol, sold under the brand name Percocet among others, is a fixed-dose combination of the opioid oxycodone with paracetamol (acetaminophen), used to treat moderate to severe pain.

<span class="mw-page-title-main">Oxymorphone</span> Opioid analgesic drug

Oxymorphone is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally. Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high potential to be abused.

<span class="mw-page-title-main">Dihydrocodeine</span> Opioid

Dihydrocodeine is a semi-synthetic opioid analgesic prescribed for pain or severe dyspnea, or as an antitussive, either alone or compounded with paracetamol (acetaminophen) or aspirin. It was developed in Germany in 1908 and first marketed in 1911.

<span class="mw-page-title-main">Dihydromorphine</span> Semi-synthetic opioid analgesic drug

Dihydromorphine is a semi-synthetic opioid structurally related to and derived from morphine. The 7,8-double bond in morphine is reduced to a single bond to get dihydromorphine. Dihydromorphine is a moderately strong analgesic and is used clinically in the treatment of pain and also is an active metabolite of the analgesic opioid drug dihydrocodeine. Dihydromorphine occurs in trace quantities in assays of opium on occasion, as does dihydrocodeine, dihydrothebaine, tetrahydrothebaine, etc. The process for manufacturing dihydromorphine from morphine for pharmaceutical use was developed in Germany in the late 19th century, with the synthesis being published in 1900 and the drug introduced clinically as Paramorfan shortly thereafter. A high-yield synthesis from tetrahydrothebaine was later developed.

Opioid-induced hyperalgesia (OIH) or opioid-induced abnormal pain sensitivity, also called paradoxical hyperalgesia, is an uncommon condition of generalized pain caused by the long-term use of high dosages of opioids such as morphine, oxycodone, and methadone. OIH is not necessarily confined to the original affected site. This means that if the person was originally taking opioids due to lower back pain, when OIH appears, the person may experience pain in the entire body, instead of just in the lower back. Over time, individuals taking opioids can also develop an increasing sensitivity to noxious stimuli, even evolving a painful response to previously non-noxious stimuli (allodynia). This means that if the person originally felt pain from twisting or from sitting too long, the person might now additionally experience pain from a light touch or from raindrops falling on the skin.

<span class="mw-page-title-main">Nicocodeine</span> Opioid analgesic and antitussive drug

Nicocodeine is an opioid analgesic and cough suppressant, an ester of codeine closely related to dihydrocodeine and the codeine analogue of nicomorphine. It is not commonly used in most countries, but has activity similar to other opiates. Nicocodeine and nicomorphine were synthesized in 1904, and introduced in 1957 by Lannacher Heilmittel of Austria. Nicocodeine is metabolised in the liver by demethylation to produce nicomorphine, also known as 6-nicotinoylmorphine, and subsequently further metabolised to morphine. Side effects are similar to those of other opiates and include itching, nausea and respiratory depression. Related opioid analogues such as nicomorphine and nicodicodeine were first synthesized. The definitive synthesis, which involves treating anhydrous codeine base with nicotinic anhydride at 130 °C, was published by Pongratz and Zirm in Monatshefte für Chemie in 1957, simultaneously with the two analogues in an article about amides and esters of various organic acids.

<span class="mw-page-title-main">Hydrocodone/paracetamol</span> Combination pain relief drug

Hydrocodone/paracetamol is the combination of the pain medications hydrocodone and paracetamol (acetaminophen). It is used to treat moderate to severe pain. It is taken by mouth. Recreational use is common in the United States.

<span class="mw-page-title-main">Codeine</span> Opiate and prodrug of morphine used to treat pain

Codeine is an opiate and prodrug of morphine mainly used to treat pain, coughing, and diarrhea. It is also commonly used as a recreational drug. It is found naturally in the sap of the opium poppy, Papaver somniferum. It is typically used to treat mild to moderate degrees of pain. Greater benefit may occur when combined with paracetamol (acetaminophen) or a nonsteroidal anti-inflammatory drug (NSAID) such as aspirin or ibuprofen. Evidence does not support its use for acute cough suppression in children. In Europe, it is not recommended as a cough medicine in those under 12 years of age. It is generally taken by mouth. It typically starts working after half an hour, with maximum effect at two hours. Its effects last for about four to six hours. Codeine exhibits abuse potential similar to other opioid medications, including a risk of addiction and overdose.

<span class="mw-page-title-main">Desmetramadol</span> Opioid painkiller medication

Desmetramadol, also known as O-desmethyltramadol (O-DSMT), is an opioid analgesic and the main active metabolite of tramadol. Tramadol is demethylated by the liver enzyme CYP2D6 to desmetramadol in the same way as codeine, and so similarly to the variation in effects seen with codeine, individuals who have a less active form of CYP2D6 will tend to have reduced analgesic effects from tramadol. Because desmetramadol itself does not need to be metabolized to induce an analgesic effect, it can be used in individuals with low CYP2D6 activity unlike tramadol.

<span class="mw-page-title-main">Tapentadol</span> Opioid analgesic of benzenoid class

Tapentadol, sold under the brand name Nucynta among others, is an opioid analgesic of the benzenoid class with a dual mode of action as an agonist of the μ-opioid receptor and as a norepinephrine reuptake inhibitor (NRI). Analgesia occurs within 32 minutes of oral administration, and lasts for 4–6 hours.

An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics. Equianalgesic charts are used for calculation of an equivalent dose between different analgesics. Tables of this general type are also available for NSAIDs, benzodiazepines, depressants, stimulants, anticholinergics and others.

<span class="mw-page-title-main">Opiate</span> Substance derived from opium

An opiate is an alkaloid substance derived from opium. It differs from the similar term opioid in that the latter is used to designate all substances, both natural and synthetic, that bind to opioid receptors in the brain. Opiates are alkaloid compounds naturally found in the opium poppy plant Papaver somniferum. The psychoactive compounds found in the opium plant include morphine, codeine, and thebaine. Opiates have long been used for a variety of medical conditions, with evidence of opiate trade and use for pain relief as early as the eighth century AD. Most opiates are considered drugs with moderate to high abuse potential and are listed on various "Substance-Control Schedules" under the Uniform Controlled Substances Act of the United States of America.

<span class="mw-page-title-main">Hydrocodone/ibuprofen</span> Combination drug

Hydrocodone/ibuprofen (INNs), sold under the brand name Vicoprofen, is a fixed-dose combination analgesic medication used in short-term therapy to relieve severe pain. Vicoprofen combines the analgesic and antitussive properties of hydrocodone with the analgesic, anti-inflammatory, and antipyretic properties of ibuprofen. In contrast to hydrocodone/acetaminophen combination analgesics such as Vicodin, this hydrocodone/ibuprofen avoids some of the liver toxicity which may occur from acetaminophen, but still presents significant dangers in hydrocodone overdose, namely respiratory depression. Vicoprofen is supplied in a fixed dose combination tablet which contains hydrocodone bitartrate, USP 7.5 mg with ibuprofen, USP 200 mg. Additional strengths of generic Vicoprofen are now available, in combinations of 5 mg/200 mg and 10 mg/200 mg respectively.

<span class="mw-page-title-main">Benzhydrocodone</span> Chemical compound

Benzhydrocodone (INN) is an opioid prodrug of the morphinan class. Its chemical structure consists of hydrocodone coupled with benzoic acid. Benzhydrocodone itself is inactive and acts as a prodrug to hydrocodone upon cleavage of the benzoate portion of the molecule.

References

  1. ↑ Bonewit-West K, Hunt SA, Applegate E (2012). Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. p. 571. ISBN   9781455701506. Archived from the original on 10 January 2023. Retrieved 20 August 2019.
  2. 1 2 3 4 5 6 7 8 Elliott JA (19 April 2016). "Opioids in the management of acute pain". In Elliott JA, Smith HS (eds.). Handbook of Acute Pain Management. CRC Press. pp. 79–. ISBN   978-1-4665-9635-1.
  3. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  4. 1 2 3 Polsten GR, Wallace MS (21 June 2016). "Analgesic Agents in Rheumatic Disease". In Firestein GS, Budd R, Gabriel SE, McInnes IB, O'Dell JR (eds.). Kelley and Firestein's Textbook of Rheumatology. Elsevier Health Sciences. pp. 1081–. ISBN   978-0-323-41494-4. Archived from the original on 12 January 2023. Retrieved 23 September 2016.
  5. 1 2 3 4 Chabner BA, Longo DL (8 November 2010). "Chapter 37: Drug Therapy of Pain in Cancer Patients". Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. pp. 700–. ISBN   978-1-60547-431-1. Archived from the original on 12 January 2023. Retrieved 23 September 2016.
  6. 1 2 3 4 5 6 7 Zhou S (6 April 2016). "Substrates of Human CYP2D6: Opioids and Opioid Receptor Antagonists". Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism. CRC Press. pp. 164–. ISBN   978-1-4665-9788-4.
  7. 1 2 3 Davis MP, Glare P, Hardy J (2005). Opioids in Cancer Pain. Oxford University Press. pp. 59–68. ISBN   978-0-19-852943-9.
  8. 1 2 Bluth MH (16 November 2016). Toxicology and Drug Testing, An Issue of Clinics in Laboratory Medicine, E-Book. Elsevier Health Sciences. pp. 85–. ISBN   978-0-323-47795-6. Archived from the original on 12 January 2023. Retrieved 22 June 2018.
  9. 1 2 Smith HS (21 February 2013). Opioid Therapy in the 21st Century. OUP USA. pp. 68–. ISBN   978-0-19-984497-5. Archived from the original on 12 January 2023. Retrieved 22 June 2018.
  10. 1 2 3 4 5 6 7 8 9 10 "Hydrocodone Bitartrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 14 November 2010. Retrieved 15 April 2019.
  11. ↑ Mallinckrodt (10 March 2021). "HYDROCODONE BITARTRATE AND ACETAMINOPHEN tablet (label)". National Institutes of Health DailyMed. Archived from the original on 6 November 2021. Retrieved 6 November 2021.
  12. ↑ Briggs GG, Freeman RK, Yaffe SJ (2011). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. p. 692. ISBN   9781608317080.
  13. ↑ "Hydrocodone Combination Products: MedlinePlus Drug Information". medlineplus.gov. Archived from the original on 5 July 2016. Retrieved 4 November 2023.
  14. ↑ "Hydrocodone: MedlinePlus Drug Information". medlineplus.gov. Archived from the original on 15 April 2019. Retrieved 15 April 2019.
  15. ↑ "Hydrocodone Use During Pregnancy". Drugs.com. Archived from the original on 28 January 2014. Retrieved 15 April 2019.
  16. ↑ "Opioid Dose Calculator". Agency Medical Directors' Group. Archived from the original on 10 February 2016. Retrieved 15 April 2019.
  17. ↑ Zacny JP, Gutierrez S (April 2009). "Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers". Drug and Alcohol Dependence. 101 (1–2): 107–114. doi:10.1016/j.drugalcdep.2008.11.013. PMID   19118954. Archived from the original on 18 January 2021. Retrieved 25 August 2020.
  18. ↑ Marco CA, Plewa MC, Buderer N, Black C, Roberts A (April 2005). "Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial". Academic Emergency Medicine. 12 (4): 282–288. doi: 10.1197/j.aem.2004.12.005 . PMID   15805317.
  19. 1 2 3 Vallejo R, Barkin RL, Wang VC (2011). "Pharmacology of opioids in the treatment of chronic pain syndromes". Pain Physician. 14 (4): E343–E360. doi: 10.36076/ppj.2011/14/E343 . PMID   21785485.
  20. ↑ "Opioid (Narcotic Analgesics and Acetaminophen Systemic )". Archived from the original on 22 March 2014. Retrieved 22 March 2014.
  21. ↑ "Labeling-Package Insert: Hydrocodone/acetaminophen 7.5 mg/325 mg" (PDF). Drugs@FDA: FDA-Approved Drugs. Chartwell. 18 October 2013. Archived (PDF) from the original on 27 April 2024. Retrieved 22 January 2024.
  22. ↑ McPherson ML (24 August 2009). "Appendix: Opioid Formulations". Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. ASHP. pp. 187–188. ISBN   978-1-58528-297-5. Archived from the original on 12 January 2023. Retrieved 23 September 2016.
  23. ↑ Odom-Forren J, Drain C (11 February 2008). PeriAnesthesia Nursing: A Critical Care Approach. Elsevier Health Sciences. pp. 751–. ISBN   978-1-4377-2610-7. Archived from the original on 12 January 2023. Retrieved 23 September 2016.
  24. ↑ Skidmore-Roth L (27 June 2013). "Hydrocodone". Mosby's Drug Guide for Nursing Students, with 2014 Update. Elsevier Health Sciences. pp. 524–. ISBN   978-0-323-22268-6. Archived from the original on 12 January 2023. Retrieved 23 September 2016.
  25. ↑ Vadivelu N, Schermer E, Kodumudi G, Berger JM (July 2016). "The Clinical Applications of Extended-Release Abuse-Deterrent Opioids". CNS Drugs. 30 (7): 637–646. doi:10.1007/s40263-016-0357-0. PMID   27290716. S2CID   26878027.
  26. 1 2 "Hydrocodone Combination Products". MedlinePlus. U.S. National Library of Medicine. 1 October 2008. Archived from the original on 5 July 2016. Retrieved 20 April 2013.
  27. ↑ Friedman RA, House JW, Luxford WM, Gherini S, Mills D (March 2000). "Profound hearing loss associated with hydrocodone/acetaminophen abuse". The American Journal of Otology. 21 (2): 188–191. doi:10.1016/S0196-0709(00)80007-1. PMID   10733182.
  28. ↑ Ho T, Vrabec JT, Burton AW (May 2007). "Hydrocodone use and sensorineural hearing loss". Pain Physician. 10 (3): 467–472. PMID   17525781. Archived from the original on 23 July 2011.
  29. ↑ Yorgason JG, Kalinec GM, Luxford WM, Warren FM, Kalinec F (June 2010). "Acetaminophen ototoxicity after acetaminophen/hydrocodone abuse: evidence from two parallel in vitro mouse models". Otolaryngology–Head and Neck Surgery. 142 (6): 814–9, 819.e1–2. doi:10.1016/j.otohns.2010.01.010. PMID   20493351. S2CID   25083914.
  30. ↑ Curhan SG, Eavey R, Shargorodsky J, Curhan GC (March 2010). "Analgesic use and the risk of hearing loss in men". The American Journal of Medicine. 123 (3): 231–237. doi:10.1016/j.amjmed.2009.08.006. PMC   2831770 . PMID   20193831.
  31. ↑ "Neonatal abstinence syndrome: MedlinePlus Medical Encyclopedia". medlineplus.gov. Archived from the original on 28 July 2017. Retrieved 11 January 2022.
  32. ↑ "Opioid Use and Opioid Use Disorder in Pregnancy". www.acog.org. Archived from the original on 11 January 2022. Retrieved 11 January 2022.
  33. 1 2 "REPREXAIN (hydrocodone bitartrate, ibuprofen) tablet, film coated". dailymed.nlm.nih.gov. NIH. Archived from the original on 6 July 2013. Retrieved 27 April 2013.
  34. ↑ Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. (April 2011). "Maternal treatment with opioid analgesics and risk for birth defects". American Journal of Obstetrics and Gynecology. 204 (4): 314.e1–314.11. doi: 10.1016/j.ajog.2010.12.039 . PMID   21345403.
  35. ↑ Wightman R, Perrone J, Portelli I, Nelson L (December 2012). "Likeability and abuse liability of commonly prescribed opioids". Journal of Medical Toxicology. 8 (4): 335–340. doi:10.1007/s13181-012-0263-x. PMC   3550270 . PMID   22992943.
  36. 1 2 3 Feng XQ, Zhu LL, Zhou Q (2017). "Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management". Journal of Pain Research. 10: 1225–1239. doi: 10.2147/JPR.S138698 . PMC   5449157 . PMID   28579821.
  37. 1 2 Kapil RP, Friedman K, Cipriano A, Michels G, Shet M, Mondal SA, et al. (October 2015). "Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet". Clinical Therapeutics. 37 (10): 2286–2296. doi: 10.1016/j.clinthera.2015.08.007 . PMID   26350273.
  38. 1 2 3 4 Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, et al. (August 2016). "Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers". Clinical Pharmacokinetics. 55 (8): 1003–1014. doi:10.1007/s40262-016-0373-8. PMC   4933729 . PMID   26895022.{{cite journal}}: CS1 maint: overridden setting (link)
  39. ↑ Gnanadesigan N, Espinoza RT, Smith RL (June 2005). "The serotonin syndrome". The New England Journal of Medicine. 352 (23): 2454–6, author reply 2454–6. doi:10.1056/NEJM200506093522320. PMID   15948273.
  40. 1 2 3 Codd EE, Shank RP, Schupsky JJ, Raffa RB (September 1995). "Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception". The Journal of Pharmacology and Experimental Therapeutics. 274 (3): 1263–1270. PMID   7562497. Archived from the original on 2 February 2017. Retrieved 21 June 2018.
  41. ↑ Filizola M, Villar HO, Loew GH (January 2001). "Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors". Bioorganic & Medicinal Chemistry. 9 (1): 69–76. doi:10.1016/S0968-0896(00)00223-6. PMID   11197347.
  42. 1 2 King TL, Miller EL (25 October 2010). "Analgesia and Anesthesia". In King TL, Brucker MC (eds.). Pharmacology for Women's Health. Jones & Bartlett Publishers. pp. 332–. ISBN   978-1-4496-1073-9.
  43. ↑ Parker RK, Hepner D, Eappin S (28 February 2014). "Chapter 27 Postoperative and Chronic Pain: Systemic and Regional Analgesic Techniques". In Chestnut DH, Wong CA, Tsen LC, Kee WD, Beilin Y, Mhyre J (eds.). Chestnut's Obstetric Anesthesia: Principles and Practice E-Book. Elsevier Health Sciences. pp. 611–. ISBN   978-0-323-11374-8. Archived from the original on 11 January 2023. Retrieved 22 June 2018.
  44. ↑ Tiziani AP (1 June 2013). "Opiod Analgesics". Havard's Nursing Guide to Drugs. Elsevier Health Sciences. pp. 933–. ISBN   978-0-7295-8162-2. Archived from the original on 11 January 2023. Retrieved 22 June 2018.
  45. ↑ Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE (February 2004). "Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors". The Journal of Pharmacology and Experimental Therapeutics. 308 (2): 547–554. doi:10.1124/jpet.103.058602. PMID   14600248. S2CID   22492018.
  46. ↑ Agar M, Clark K (10 February 2015). "Palliative Medicine". In Talley NJ, Frankum B, Currow D (eds.). Essentials of Internal Medicine (3rd ed.). Elsevier Health Sciences. pp. 491–. ISBN   978-0-7295-8081-6.
  47. ↑ "Instructions for Mean Equivalent Daily Dose (MEDD)" (PDF). Archived from the original (PDF) on 27 July 2011. Retrieved 22 August 2010.
  48. ↑ Hydrocodone Bitartrate and Acetaminophen Tablets, USP 5 mg/325 mg CII Archived 22 February 2024 at the Wayback Machine fda.gov
  49. ↑ Raffa RB, Colucci R, Pergolizzi JV (September 2017). "The effects of food on opioid-induced nausea and vomiting and pharmacological parameters: a systematic review". Postgraduate Medicine. 129 (7): 698–708. doi:10.1080/00325481.2017.1345282. PMID   28635354. S2CID   46184629.
  50. ↑ Bond M, Rabinovich-Guilatt L, Selim S, Darwish M, Tracewell W, Robertson P, et al. (December 2017). "Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects". Clinical Drug Investigation. 37 (12): 1153–1163. doi:10.1007/s40261-017-0575-3. PMID   28948482. S2CID   32440860.{{cite journal}}: CS1 maint: overridden setting (link)
  51. ↑ Farr SJ, Robinson CY, Rubino CM (2015). "Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers". Clinical Pharmacology. 7: 1–9. doi: 10.2147/CPAA.S70831 . PMC   4307648 . PMID   25653563.
  52. ↑ Devarakonda K, Kostenbader K, Giuliani MJ, Young JL (November 2015). "Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials". BMC Pharmacology & Toxicology. 16: 31. doi: 10.1186/s40360-015-0032-y . PMC   4662814 . PMID   26614499.
  53. ↑ Jenkins AJ (9 October 2007). "Pharmacokinetics of Specific Drugs". In Karch SB (ed.). Pharmacokinetics and Pharmacodynamics of Abused Drugs. CRC Press. pp. 56–. ISBN   978-1-4200-5460-6. Archived from the original on 12 January 2023. Retrieved 23 September 2016.
  54. ↑ Broussard LA (22 January 2013). "Challenges in Confirmation Testing for Drugs of Abuse". In Dasgupta A, Sepulveda JL (eds.). Accurate Results in the Clinical Laboratory: A Guide to Error Detection and Correction. Newnes. pp. 239–. ISBN   978-0-12-415858-0.
  55. 1 2 Sepulveda JL (23 April 2012). "Genetic Aspect of Opiate Metabolism and Addiction". In Dasgupta A, Langman LJ (eds.). Pharmacogenomics of Alcohol and Drugs of Abuse. CRC Press. pp. 175–. ISBN   978-1-4398-5611-6. Archived from the original on 12 January 2023. Retrieved 23 September 2016.
  56. ↑ Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, et al. (April 1997). "Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability". The Journal of Pharmacology and Experimental Therapeutics. 281 (1): 103–108. PMID   9103485.
  57. ↑ Gardiner SJ, Begg EJ (September 2006). "Pharmacogenetics, drug-metabolizing enzymes, and clinical practice". Pharmacological Reviews. 58 (3): 521–590. doi:10.1124/pr.58.3.6. PMID   16968950. S2CID   25747320.
  58. ↑ Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. (February 2012). "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype". Clinical Pharmacology and Therapeutics. 91 (2): 321–326. doi:10.1038/clpt.2011.287. PMC   3289963 . PMID   22205192.{{cite journal}}: CS1 maint: overridden setting (link)
  59. ↑ Navani DM, Yoburn BC (November 2013). "In vivo activity of norhydrocodone: an active metabolite of hydrocodone". The Journal of Pharmacology and Experimental Therapeutics. 347 (2): 497–505. doi:10.1124/jpet.113.207548. PMID   23995596. S2CID   31072872.
  60. ↑ Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, et al. (October 2010). "Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions". Pediatrics. 126 (4): e986–e989. doi:10.1542/peds.2009-1907. PMID   20837591. S2CID   42365304.{{cite journal}}: CS1 maint: overridden setting (link)
  61. ↑ Vuilleumier PH, Stamer UM, Landau R (2012). "Pharmacogenomic considerations in opioid analgesia". Pharmacogenomics and Personalized Medicine. 5: 73–87. doi: 10.2147/PGPM.S23422 . PMC   3513230 . PMID   23226064.
  62. ↑ Spiller HA (March 2003). "Postmortem oxycodone and hydrocodone blood concentrations". Journal of Forensic Sciences. 48 (2): 429–431. doi:10.1520/JFS2002309. PMID   12665006.
  63. ↑ Baselt RC (2017). Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications. pp. 1050–1052. ISBN   978-0-692-77499-1.
  64. ↑ Carroll RJ, Leisch H, Rochon L, Hudlicky T, Cox DP (January 2009). "One-pot conversion of thebaine to hydrocodone and synthesis of neopinone ketal". The Journal of Organic Chemistry. 74 (2): 747–752. doi:10.1021/jo802454v. PMID   19072148.
  65. ↑ Sinatra RS (6 December 2010). The Essence of Analgesia and Analgesics. Cambridge: Cambridge University Press. pp. 73, 81. ISBN   9780511841378.
  66. ↑ Cruz SL (27 October 2016). Neuroscience in the 21st Century. New York, NY: Springer. pp. 3626, 3657. ISBN   978-1-4939-3474-4.
  67. ↑ Mannich C, Löwenheim H (1920). "Ueber zwei neue Reduktionsprodukte des Kodeins". Archiv der Pharmazie . 258 (2–4): 295–316. doi:10.1002/ardp.19202580218. ISSN   0365-6233. S2CID   97513395. Archived from the original on 1 August 2020. Retrieved 12 September 2019.
  68. ↑ "Drugs@FDA—Approval History: Hycodan". FDA. Archived from the original on 28 August 2021. Retrieved 7 January 2006.
  69. ↑ "FDA Docket No. 2007N-0353, Drug Products Containing Hydrocodone; Enforcement Action Dates". FDA. Archived from the original on 12 January 2008. Retrieved 7 January 2006. See section I. B., DESI Review of Hydrocodone Products
  70. ↑ "Dihydromorphine". PubChem. U.S. National Library of Medicine. Archived from the original on 14 July 2014. Retrieved 21 May 2021.
  71. ↑ "Dihydrocodeine". PubChem. U.S. National Library of Medicine. Archived from the original on 21 May 2021. Retrieved 21 May 2021.
  72. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 526. ISBN   9783527607495. Archived from the original on 14 January 2023. Retrieved 25 August 2020.
  73. ↑ "Making Some Painkillers Harder to Get" . The New York Times. 21 February 2013. Archived from the original on 3 January 2022. Retrieved 15 April 2019.
  74. ↑ "Hydrocodone - Drug Usage Statistics". ClinCalc. Archived from the original on 13 November 2022. Retrieved 7 October 2022.
  75. ↑ International Narcotics Control Board Report 2008. United Nations Pubns. 2009. p. 20. ISBN   978-9211482324.[ permanent dead link ]
  76. ↑ "Hydrocodone Combination Products". MedlinePlus. The American Society of Health-System Pharmacists, Inc. Archived from the original on 5 July 2016. Retrieved 14 July 2018.
  77. ↑ McCarthy M (January 2016). "Prescriptions for hydrocodone plummet after US tightens prescribing rules". BMJ. 352: i549. doi:10.1136/bmj.i549. PMID   26819247. S2CID   45954090.
  78. ↑ Jones CM, Lurie PG, Throckmorton DC (March 2016). "Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing". JAMA Internal Medicine. 176 (3): 399–402. doi: 10.1001/jamainternmed.2015.7799 . PMID   26809459.
  79. ↑ Chambers J, Gleason RM, Kirsh KL, Twillman R, Webster L, Berner J, et al. (September 2016). "An Online Survey of Patients' Experiences Since the Rescheduling of Hydrocodone: The First 100 Days". Pain Medicine. 17 (9): 1686–1693. doi: 10.1093/pm/pnv064 . PMID   26814291.{{cite journal}}: CS1 maint: overridden setting (link)
  80. ↑ "Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II". Federal Register. 22 August 2014. Archived from the original on 11 August 2017. Retrieved 11 August 2017.
  81. ↑ "Drug-Related Hospital Emergency Room Visits". National Institute on Drug Abuse. Archived from the original on 11 August 2017. Retrieved 11 August 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.